Sign In
Buy IFRX
$1.70
-0.0200 (-1.16%)
At Close: Jul 31, 2026
BYND, ALC among premarket gainers
02:13pm, Wednesday, 26'th Feb 2020
SELLAS Life Sciences Group (NASDAQ:SLS) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia.Alcon (NYSE:ALC) +10% on Q4 results.Moderna (NASDAQ:MRNA) +9%�
24 Healthcare Stocks Moving In Wednesday's Pre-Market Session
01:01pm, Wednesday, 26'th Feb 2020
Gainers
Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) stock moved upwards by 65.7% to $0.67 during Wednesday's pre-market session.
InflaRx, Inc. (NASDAQ: IFRX) stock...
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
12:30pm, Wednesday, 26'th Feb 2020
InflaRx to present initial data at the SVB Leerink Global Healthcare Conference today at 9:00 am EST (3:00 pm CET). JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a clinical-
InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference
01:00pm, Wednesday, 19'th Feb 2020
JENA, Germany, Feb. 19, 2020 -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement.
Inflarx NV (NASDAQ:IFRX) Receives Average Recommendation of "Hold" from Analysts
06:26am, Friday, 17'th Jan 2020
Inflarx NV (NASDAQ:IFRX) has earned an average rating of “Hold” from the eleven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated t
Inflarx (NASDAQ:IFRX) Cut to Hold at Zacks Investment Research
06:42am, Tuesday, 14'th Jan 2020
Inflarx (NASDAQ:IFRX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. Acc
Inflarx (NASDAQ:IFRX) Upgraded by Zacks Investment Research to Buy
09:04am, Friday, 10'th Jan 2020
Inflarx (NASDAQ:IFRX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The
InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference
12:30pm, Thursday, 09'th Jan 2020
JENA, Germany, Jan. 09, 2020 -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement.
InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference
12:30pm, Thursday, 09'th Jan 2020
JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory...
Did Hedge Funds Drop The Ball On InflaRx N.V. (IFRX) ?
12:45am, Saturday, 21'st Dec 2019
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do n
InflaRx Reports Third Quarter 2019 Financial & Operating Results
12:30pm, Thursday, 07'th Nov 2019
Recently announced results of open label extension part of SHINE Phase IIb study confirm potential of IFX-1 in Hidradenitis Suppurativa and warrant evaluation of future development Company announces u
The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs
12:18pm, Thursday, 07'th Nov 2019
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on ra
InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa
07:10am, Thursday, 07'th Nov 2019
70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment) 78.2% of OLE patients complete ext
Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
12:43pm, Thursday, 17'th Oct 2019
We can readily understand why investors are attracted to unprofitable companies. For example, although...
InflaRx Reports Second Quarter 2019 Financial & Operating Results
08:05pm, Wednesday, 14'th Aug 2019
IFX-1 in Hidradenitis Suppurativa did not meet the primary endpoint; trial ongoing - multiple efficacy signals for high-dose group identifiedFirst patient treated in Pyoderma.
